Novartis expands its U.S. radioligand therapy network with a major new facility in Texas, aiming to improve access to advanced cancer treatments and strengthen domestic pharmaceutical manufacturing
Denton, Texas, 8 May 2026 – Global healthcare company Novartis has officially begun construction on a new radioligand therapy manufacturing facility in Denton, Texas, marking another major step in the company’s growing investment in advanced cancer treatment infrastructure across the United States.
The new 46,000 square foot facility will become Novartis’ first manufacturing site in Texas dedicated to radioligand therapy, also known as RLT. The site is expected to begin operations in 2028 and will support the production of precision cancer treatments designed to target tumors more accurately while reducing damage to healthy cells.
Radioligand therapy is gaining attention across the pharmaceutical and biotech industries because it combines targeted molecules with radiation to directly attack cancer cells. Experts believe this technology could play a major role in the future of oncology care, especially for patients with advanced or difficult-to-treat cancers.
The Denton facility will be Novartis’ fifth radioligand therapy manufacturing site in the United States. It will join the company’s existing network in New Jersey, Indiana, and California, along with another recently announced facility in Florida. The expansion is part of Novartis’ broader multi-billion-dollar investment strategy focused on strengthening pharmaceutical manufacturing and research capabilities in the U.S.
According to the company, the Texas site will create new opportunities in bioengineering, advanced manufacturing, quality assurance, and operations. Local leaders expect the investment to contribute to regional economic growth while helping position Texas as a stronger biotechnology and life sciences hub.
One of the biggest challenges in radioligand therapy is speed. These treatments are highly time sensitive and often custom-made for individual patients. Manufacturing facilities need to be located strategically so therapies can be delivered quickly and efficiently to hospitals and cancer centers. By expanding its coast-to-coast manufacturing network, Novartis aims to improve reliability and patient access across the country.
The company is also continuing to explore radioligand therapies for several cancer types, including prostate, breast, colon, lung, pancreatic, and brain cancers. Industry analysts say demand for targeted oncology therapies is expected to grow significantly over the next decade as healthcare providers increasingly adopt precision medicine approaches.
The groundbreaking in Denton highlights how pharmaceutical companies are investing heavily in innovative therapies, domestic manufacturing, and advanced healthcare technology to meet rising patient demand and improve treatment outcomes.
